Effect of Medroxy progesteron in Chronic Obstructive Pulmonary Disease (COPD) exacerbation

Evaluation of the effectiveness of medroxyprogesterone on blood gases and short term hospital outcomes in patients with Chronic Obstructive Pulmonary Disease (COPD) exacerbation who received Non Invasive Ventilation (NIV)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20211031052922N1

Enrollment

Registered

2021-12-01

Start date

2021-08-23

Completion date

Unknown

Last updated

2022-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease(COPD) Exacerbation. Chronic obstructive pulmonary disease with acute exacerbation, unspecified

Interventions

Intervention 1: Intervention group: prescription medroxy pogesteron acetate 15mg per 6 hour until 5days to COPD (Chronic Obstructive Pulmonary Disease)exacerbation patients who needs Non InvasiveVenti

Eligibility

Sex/Gender

All

Age

30 Years to 80 Years

Inclusion criteria

Inclusion criteria: Chronic Obstructive Pulmonary Disease (COPD) exacerbation patients who has one of this criteria(dyspnea, increased sputum volume, and a change in the nature of sputum) COPD exacerbation patient who needs Non Invasive Ventilation (NIV) Age between 30-80 Signing the written informed consent

Exclusion criteria

Exclusion criteria: Requiring mechanical ventilation by the time of admission Having a current or history of thromboembolic diseases like Pulmonary Thrombosis Embolie (PTE), active thrombophelebitis, Deep Vein Thrombosis (DVT) History of cerebrovascular disease, history of myocardial infarction (MI) and stroke Unexplained vaginal bleeding Hepatic diseases Pregnancy History of breast cancer or any estrogen or progesterone dependent tumors History of allergy to hormonal drugs containing progesterone Stable and frequent vomiting Decreased level of consciousness Deformity or trauma in face

Design outcomes

Primary

Measure	Time frame
ICU admission. Timepoint: Daye1;3;5. Method of measurement: doctors reports.;Intubation. Timepoint: Days1,3,5. Method of measurement: Doctors reports.;Venous blood gase. Timepoint: Days1,3,5. Method of measurement: ABG analysor.;O2saturation. Timepoint: Days1,3,5. Method of measurement: Pulse oximetery.	—

Secondary

Measure	Time frame
Hospitalization days. Timepoint: In day 5 and days of discharge. Method of measurement: Days of hospitalization.;Dyspnea score. Timepoint: Days 1,3,5. Method of measurement: Borg scale.;Non Invasive Ventilation(NIV) hours/day usage. Timepoint: Days 1,3,5. Method of measurement: Based on doctors reports.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMina Nickpour

Esfahan University of Medical Sciences

minanickpour@yahoo.com+98 31 3263 8279

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026